Pipeline
Zervimesine: Targeting Toxic Protein Binding in Neural Pathways
cogrx.comCrawled Nov 18, 2026
Zervimesine: Targeting Toxic Protein Binding in Neural Pathways
Alzheimer’s disease is believed to be caused, in part, by the age-related buildup of proteins including amyloid beta (Aβ).
The Phase 2 START study has enrolled 540 participants aged 50 to 85 with mild cognitive impairment or early-stage Alzheimer’s disease. Participants receive either a placebo or zervimesine (CT1812), with eligibility for those on stable approved immunotherapies.
Zervimesine: A Long-Needed Approach to Addressing DLB
The “Conversations” video series will feature virtual fireside chats with neuroscience experts who will discuss advances in the research and treatment of Alzheimer’s disease, dementia with Lewy bodies (DLB), and other age-related neurodegenerative conditions.
Foundational Principles of Neuroscience:
Interview with Lisa Ricciardi at H.C. Wainwright Global Investment Conference BiotechTV October 29, 2026
Cognition Therapeutics named Ms. Ricciardi to its Board of Directors in March 2019 and appointed her CEO in 2020. She led the company through its initial public offering and has experience in drug development, healthcare services, and genomics.
Founding director of the Comprehensive Center for Brain Health at University of Miami Miller School of Medicine
Ellen B. Richstone joined the Cognition Therapeutics board of directors in November 2021 and serves as the chair of the audit committee.
Cognition Therapeutics, Inc. is a clinical-stage neuroscience company developing oral medications designed to treat neurodegenerative disorders
2500 Westchester Avenue Purchase, NY 10577 United States
Cognition Therapeutics defines a financial conflict of interest as a significant financial interest held by its investigators or key personnel that could compromise their independence in research design, conduct, or reporting.